US FDA approves syringe version of Argenx's immune disorder drug
10/04/2025 22:51
April 10 (Reuters) - The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's ARGX.BR blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option of at-home self administration, the company said on Thursday. (Reporting by Kamal Choudhury and Mariam Sunny in Bengaluru; Editing by Tasim Zahid and Alan Barona) ((Kamal.Choudhury@thomsonreuters.com))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles